Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

5.770 +0.090 (+1.58%)

Streaming Delayed Price Updated: 1:53 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 Next >

Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index ↗

December 17, 2021

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:

Via Benzinga

North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026

December 14, 2021

Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...

Via FinancialNewsMedia

Compass Pathways (NASDAQ: CMPS) Announces Promising Data from Psilocybin Therapy Trial

December 13, 2021

Via Investor Brand Network

Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms ↗

December 13, 2021

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:

Via Benzinga

Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline ↗

December 12, 2021

The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...

Via Talk Markets

Topics Cannabis

Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways

December 07, 2021

Via Investor Brand Network

Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways ↗

December 06, 2021

Coda Signature Taps Teddy C. Scott As Board Member Producer of cannabis-infused edibles and wellness products Coda Signature

Via Benzinga

Topics Cannabis

New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers ↗

December 03, 2021

In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “

Via Benzinga

Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November ↗

December 01, 2021

A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance.

Via Talk Markets

Topics Cannabis

COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction ↗

December 01, 2021

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher...

Via Benzinga

Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways ↗

November 29, 2021

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ...

Via Benzinga

Were Compass Pathways' Clinical Trial Results Really That Bad? ↗

November 28, 2021

The biotech was priced for perfection; its data wasn't.

Via The Motley Fool

10 Biggest Price Target Changes For Monday ↗

November 22, 2021

MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...

Via Benzinga

Better Buy: Compass Pathways vs. Jazz Pharmaceuticals ↗

November 21, 2021

Both of these biotech stocks are innovators, but one is more likely to hit it out of the park.

Via The Motley Fool

Psychedelic Drug Stocks Continued To Decline Last Week ↗

November 21, 2021

The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.

Via Talk Markets

How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions ↗

November 16, 2021

Image by Mathew Schwartz from Unsplash The following post was written and/or pu...

Via Benzinga

Is Now the Right Time to Buy Compass Pathways? ↗

November 13, 2021

Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted.

Via The Motley Fool

Why Compass Pathways Stock Slumped This Week ↗

November 12, 2021

Positive trial results weren't enough to keep the company's shares from sinking this week.

Via The Motley Fool

Use of Ketamine for Mental Disorders Rising While New Therapies Emerge

November 17, 2021

Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion...

Via FinancialNewsMedia

Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗

November 11, 2021

Compass Pathways reported

Via Talk Markets

Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential ↗

November 11, 2021

Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.

Via InvestorPlace

Is Compass Pathways Stock a Once-in-a-Lifetime Bargain? ↗

November 11, 2021

Investors might want to give this psychedelic stock another look.

Via The Motley Fool

75 Biggest Movers From Yesterday ↗

November 10, 2021

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...

Via Benzinga

COMPASS Pathways plc (CMPS) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

CMPS earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Why Compass Pathways Shares Are Slumping More Than 22% Tuesday ↗

November 09, 2021

The stock dropped more than $13 on Tuesday.

Via The Motley Fool

Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial ↗

November 09, 2021

Shares plunged, despite a psilocybin-based drug reducing depression in a trial.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 09, 2021

Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency...

Via Benzinga

EXCLUSIVE: Benzinga Interviews Mind Cure CEO Kelsey Ramsden with Updates on Latest Press Release ↗

November 09, 2021

Image by: iStock The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored conte...

Via Benzinga

Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial ↗

November 09, 2021

Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has...

Via Benzinga

58 Stocks Moving In Monday's Mid-Day Session ↗

November 09, 2021

Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash. TDH...

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.